Mural Oncology plc (MURA) NASDAQ

2.08

+0(+0.00%)

Updated at September 18 04:00PM

Currency In USD

Mural Oncology plc

Address

10 Earlsfort Terrace

Dublin, D02 T380

Ireland

Phone

353 1 905 8020

Sector

Healthcare

Industry

Biotechnology

Employees

116

First IPO Date

November 16, 2023

Key Executives

NameTitlePayYear Born
Ms. Caroline J. Loew Ph.D.President, Chief Executive Officer & Director1.01M1971
Mr. Adam D. Cutler B.A.Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer735,2501975
Dr. Vicki L. Goodman M.D.Chief Medical Officer987,2501971
Ms. Maiken Keson-BrookesChief Legal Officer01973
Mr. Justin LevineHead of Human Resources & Vice President of Human Resources0N/A

Description

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.